Open Access

Erratum to: Age, atherosclerosis and type 2 diabetes reduce human mesenchymal stromal cell-mediated T-cell suppression

  • Ozge Kizilay Mancini1,
  • Dominique Shum-Tim2,
  • Ursula Stochaj3,
  • José A. Correa4 and
  • Inés Colmegna5, 6Email author
Stem Cell Research & Therapy20178:35

DOI: 10.1186/s13287-017-0504-7

Received: 8 February 2017

Accepted: 8 February 2017

Published: 14 February 2017

The original article was published in Stem Cell Research & Therapy 2015 6:140

Erratum

The original article [1] contains a mistakenly shortened abstract due to a misinterpretation during its production.

As such, the full abstract should read as follows:

Abstract

Atherosclerosis is an age-associated, multifactorial process driven by immune activation and inflammation. Ongoing clinical trials aim to establish the role of mesenchymal stromal cells (MSCs) as therapeutic agents in atherosclerosis. The beneficial effects of MSCs derive from their immune-modulatory properties. Understanding the impact of aging and age-associated conditions (i.e., type 2 diabetes mellitus and atherosclerosis) on MSC function is key to maximizing their therapeutic potency. The aim of this study was to assess the effect of chronological and biological aging on human MSC-mediated CD4+ T-cell suppression. To this end human MSCs were isolated from adipose tissue and the MSC:CD4+ T-cell suppression was assessed in a co-culture system. MSCs from elderly donors (≥65 years) had significantly lower T-cell suppressive capacity compared to those from donors <65 years (p = 0.003). Furthermore, MSCs from patients with atherosclerosis and type 2 diabetes mellitus were less efficient at suppressing T-cell proliferation (atherosclerosis, p = 0.02; type 2 diabetes mellitus, p = 0.04; compared to non-disease controls). Sex and tobacco use did not impact the immunosuppressive capacity of MSCs. In summary, this study demonstrates that advanced age, atherosclerosis and type 2 diabetes mellitus reduce the functional potency of MSCs. Optimizing the criteria for the selection of MSC donors could enhance the results of cell-based therapies.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Anatomy and Cell Biology, McGill University
(2)
Division of Cardiothoracic Surgery and Surgical Research, Royal Victoria Hospital, McGill University Health Center
(3)
Department of Physiology, McGill University
(4)
Department of Mathematics and Statistics, McGill University
(5)
Division of Rheumatology, Department of Medicine, McGill University
(6)
Royal Victoria Hospital, McGill University Health Centre

Reference

  1. Kizilay M, et al. Age, atherosclerosis and type 2 diabetes reduce human mesenchymal stromal cell-mediated T-cell suppression. Stem Cell Res Ther. 2015;6:140.View ArticleGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement